The figures below come from SURMOUNT-1, the pivotal global trial of the tirzepatide molecule in adults with obesity or overweight. Tizaro contains the same active ingredient — individual results vary by dose, lifestyle, and medical supervision.
Weight reduction with Tizaro builds gradually as your dose is titrated upward and your body adjusts. Here's a general pattern observed in clinical practice.
Reduced hunger and smaller portions become noticeable as the starting 2.5mg dose takes effect.
Most patients see their first clear drop on the scale, typically 3–6% of starting body weight.
As doses increase under medical guidance, weight loss accelerates — commonly reaching double digits in % terms.
Weight loss typically slows and stabilises; your doctor helps plan long-term maintenance, with or without continued treatment.
• Dose: Higher doses of Tirzepatide are more effective than lower doses. If you have side effects, you might stay on a lower dose and increase gradually.
• Lifestyle Changes: Combining Tizaro with a balanced, calorie-controlled diet and regular exercise maximizes results.
• Individual Metabolism: Everyone's body responds to Tirzepatide at a slightly different rate
Tirzepatide's weight-loss effect outperforms single-pathway GLP-1 medicines in head-to-head data, largely due to the added GIP activity.
Both GLP-1 and GIP receptors exist in brain regions controlling hunger and reward. Dual activation produces a stronger, more consistent reduction in food intake than single-pathway drugs.
GIP receptor activity is believed to directly influence how fat cells store and release energy, contributing to fat loss beyond what reduced appetite alone would explain.
The titration schedule that takes patients from 2.5mg to these results.